That has spread to other parts of the body or cannot be removed by surgery, and whose tumor is KRAS G12C positive, and who have received at least one prior treatment.1

ABOUT
LUMAKRAS®

HOW DOES LUMAKRAS® WORK?

Lumakras icon
  • LUMAKRAS® is specifically designed for tumors with the KRAS G12C mutation in non-small cell lung cancer (NSCLC)1
  • In tumors with this KRAS mutation, the protein remains mostly in an “on” position, and cells are continuously forced to grow2
  • LUMAKRAS® targets the mutated KRAS molecule and locks it in the “off” position. This may prevent tumor cell growth3
green-round-icon

If your non-small cell lung cancer is KRAS G12C positive and has been treated with a prior therapy, such as chemotherapy or immunotherapy, ask your doctor if LUMAKRAS® may be able to help.1

NEXT: CLINICAL TRIAL RESULTS
×
Amgen stands with our local Los Angeles community. Click here to learn what we are doing to support and contact us if the fires have impacted your access to Amgen medication.

Important Safety Information

What should I tell my healthcare provider before taking LUMAKRAS®?

  • Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
    • have liver problems.
    • have lung or breathing problems other than lung cancer.
    • are pregnant or plan to become pregnant. It is not known if LUMAKRAS® will harm your unborn baby.
    • are breastfeeding or plan to breastfeed. It is not known if LUMAKRAS® passes into your breast milk.
      Do not breastfeed during treatment with LUMAKRAS® and for 1 week after the final dose.
  • Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary and herbal supplements. LUMAKRAS® can affect the way some other medicines work, and some other medicines can affect the way LUMAKRAS® works.
  • Especially tell your healthcare provider if you take antacid medicines, including Proton Pump Inhibitor (PPI) medicines or H2 blockers during treatment with LUMAKRAS®. Ask your healthcare provider if you are not sure.

LUMAKRAS® may cause serious side effects, including:

  • Liver problems: LUMAKRAS® may cause abnormal liver blood test results. Your healthcare provider should do blood tests before starting and during treatment with LUMAKRAS® to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including: your skin or the white part of your eyes turns yellow (jaundice), dark or “tea-colored” urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, and pain, aching, or tenderness on the right side of your stomach-area (abdomen).
  • Lung or breathing problems: LUMAKRAS® may cause inflammation of the lungs that can lead to death.
    Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough or fever.
  • Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LUMAKRAS® if you develop side effects.

The most common side effects

  • The most common side effects of LUMAKRAS® include diarrhea, muscle or bone pain, nausea, tiredness, liver problems, cough, changes in liver function tests, and changes in certain blood tests.
  • These are not all the possible side effects of LUMAKRAS®. Call your doctor for medical advice about side effects.

What is LUMAKRAS®?

LUMAKRAS® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC):

  • that has spread to other parts of the body or cannot be removed by surgery, and
  • whose tumor has an abnormal KRAS G12C gene, and
  • who have received at least one prior treatment for their cancer.

Your healthcare provider will perform a test to make sure that LUMAKRAS® is right for you.
It is not known if LUMAKRAS® is safe and effective in children.

Please see LUMAKRAS® Patient Information.

LUMAKRAS® is a trademark of Amgen Inc.

References: 1. LUMAKRAS® (sotorasib) Patient Information. Thousand Oaks, CA: Amgen 2021. 2. Hong DS, Fakih MG, Strickler JH, et. al. N Engl J Med. 2020. 3. LUMAKRAS® (sotorasib) Prescribing Information. Thousand Oaks, CA: Amgen 2021.

Important Safety Information

What should I tell my healthcare provider before taking LUMAKRAS®?

  • Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
    • have liver problems.
    • have lung or breathing problems other than lung cancer.

Important Safety Information

What should I tell my healthcare provider before taking LUMAKRAS®?

  • Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
    • have liver problems.
    • have lung or breathing problems other than lung cancer.

Important Safety Information

What should I tell my healthcare provider before taking LUMAKRAS®?

  • Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
    • have liver problems.
    • have lung or breathing problems other than lung cancer.
    • are pregnant or plan to become pregnant. It is not known if LUMAKRAS® will harm your unborn baby
    • are breastfeeding or plan to breastfeed. It is not known if LUMAKRAS® passes into your breast milk.
      Do not breastfeed during treatment with LUMAKRAS® and for 1 week after the final dose.
  • Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary and herbal supplements. LUMAKRAS® can affect the way some other medicines work, and some other medicines can affect the way LUMAKRAS® works.
  • Especially tell your healthcare provider if you take antacid medicines, including Proton Pump Inhibitor (PPI) medicines or H2 blockers during treatment with LUMAKRAS®. Ask your healthcare provider if you are not sure.

LUMAKRAS® may cause serious side effects, including:

  • Liver problems: LUMAKRAS® may cause abnormal liver blood test results. Your healthcare provider should do blood tests before starting and during treatment with LUMAKRAS® to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including: your skin or the white part of your eyes turns yellow (jaundice), dark or “tea-colored” urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, and pain, aching, or tenderness on the right side of your stomach-area (abdomen).
  • Lung or breathing problems: LUMAKRAS® may cause inflammation of the lungs that can lead to death.
    &nbsb: Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough or fever.
  • Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LUMAKRAS® if you develop side effects.

The most common side effects

  • The most common side effects of LUMAKRAS® include diarrhea, muscle or bone pain, nausea, tiredness, liver problems, cough, changes in liver function tests, and changes in certain blood tests.
  • These are not all the possible side effects of LUMAKRAS®. Call your doctor for medical advice about side effects.

What is LUMAKRAS®?

LUMAKRAS® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC):

  • that has spread to other parts of the body or cannot be removed by surgery, and
  • whose tumor has an abnormal KRAS G12C gene, and
  • who have received at least one prior treatment for their cancer.

Your healthcare provider will perform a test to make sure that LUMAKRAS® is right for you.
It is not known if LUMAKRAS® is safe and effective in children.

Please see LUMAKRAS® Patient Information.

LUMAKRAS® is a trademark of Amgen Inc.